AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05728476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conbercept intravitreal injection
Description: Patients will receive three monthly intravitreal injections of 0.5 mg Conbercept (Chengdu Kanghong Biotech Co.) with a 30-gauge syringe needle approximately 3.5-4 mm posterior to the corneal limbus under topical anesthesia.
Study NCT04716985 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MOLECULAR HYDROGEN
Description: Magnesium Tablet
Study NCT04716985 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO MAGNESIUM
Description: Magnesium carbonate tablet
Study NCT05025930 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endoscopic surgical instrument control system (SP1000: single-port laparoscopy)
Description: The system will be used in conjunction with other equipment during endoscopic surgery to accurately control endoscopic surgical instruments and perform delicate surgical procedures such as grasping, cutting, blunt separation, hemostasis, ligation and suture.
Study NCT05025930 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic surgical instrument control system (IS3000: multi-port laparoscopy)
Description: The system will be used in conjunction with other equipment during endoscopic surgery to accurately control endoscopic surgical instruments and perform delicate surgical procedures such as grasping, cutting, blunt separation, hemostasis, ligation and suture.
Study NCT06157450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273
Description: Participants receive ZSP1273 orally.
Study NCT06529055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Pouch - Nicotine
Description: Ingestion of a randomized oral nicotine pouch
Study NCT06529055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Pouch - Caffeine
Description: Ingestion of a randomized oral caffeine pouch
Study NCT06529055 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral Pouch - Placebo
Description: Ingestion of a randomized oral placebo pouch
Study NCT05221359 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExOlin®
Description: Implantation of ExOlin® device, safety follow-up followed by a treatment period in which device is used to administer insulin.~Device explanted with a safety follow-up.
Study NCT05221359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: Use of NovoRapid insulin during all periods of the clinical investigations
Study NCT05299697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG103 15 mg
Description: Administered subcutaneously (s.c., under the skin) as well as calorie restrict diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 15 mg.
Study NCT05299697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG103 22.5 mg
Description: Administered subcutaneously (s.c., under the skin) as well as calorie restrict diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg, 15 mg to 22.5 mg.
Study NCT05299697 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously (s.c., under the skin) as well as calorie restrict diet and increased physical activity for 24 weeks.
Study NCT04892914 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embr thermal device
Description: Participants use the Embr thermal device for 4 weeks
Study NCT04709952 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation_High real
Description: Transcranial DCS (tDCS) is applied to patients with depressive disorder taking antidepressants in high real stimulation group (2mA).
Study NCT04709952 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation_Low real
Description: Transcranial DCS (tDCS) is applied to patients with depressive disorder taking antidepressants in Low real stimulation group (1mA).
Study NCT04709952 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation_Sham
Description: Transcranial DCS (tDCS) is applied to patients with depressive disorder taking antidepressants in sham stimulation group (0mA).
Study NCT05267431 — intervention group
Intervention type: DRUG
Intervention: Biological Drug
Description: Different biological drugs
Study NCT05216575 — intervention group
Intervention type: DRUG
Intervention: Administration of Almitrine
Description: Administration of Almitrine (intravenous bolus of 0.5 mg/kg over 30 minutes followed by a continuous perfusion of 16 mg/kg/min in responders)
Study NCT04879368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Oral multi-targeted tyrosine kinase inhibitor (TKI) which targets angiogenic (VEGF, TIE-2), stromal (PDGF-β), and oncogenic (RAF, RET and KIT) receptor tyrosine kinases
Study NCT04879368 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: human IgG4 monoclonal antibody inhibitor of PD-1
Study NCT04879368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel is taxane-derivative chemotherapy drug, used in the treatment of early, locally advanced and metastatic breast cancer. It is an anti-microtubule agent. Other uses are in the treatment of non-small cell lung cancer, advanced stomach cancer, head and neck cancers, soft tissue sarcoma, ovarian cancer, metastatic prostate cancer, etc.~microtubules, and simultaneously promotes assembly and inhibits disassembly of them
Study NCT04879368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel is one of several cytoskeletal drugs that target tubulin. Paclitaxel-treated cells have defects in mitotic spindle assembly, chromosome segregation, and cell division. Unlike other tubulin-targeting drugs, such as colchicine, that inhibit microtubule assembly, paclitaxel stabilizes the microtubule polymer and protects it from disassembly. Chromosomes are thus unable to achieve a metaphase spindle configuration. This blocks the progression of mitosis and prolonged activation of the mitotic checkpoint triggers apoptosis or reversion to the G0-phase of the cell cycle without cell division
Study NCT04879368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Camptothecin, one of the four major structural classifications of plant-derived anti-cancerous compounds, is a cytotoxic alkaloid which consists of a pentacyclic ring structure containing a pyrrole (3, 4 β) quinoline moiety, an S-configured lactone form, and a carboxylate form. Irinotecan is activated by hydrolysis to SN-38, an inhibitor of topoisomerase I. This is then inactivated by glucuronidation by uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1). The inhibition of topoisomerase I by the active metabolite SN-38 eventually leads to inhibition of both DNA replication and transcription.
Study NCT04879368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trifluridine/Tipracil
Description: The drug consists of the cytotoxin trifluridine and the thymidine phosphorylase inhibitor (TPI) tipiracil. Trifluridine is incorporated into DNA during DNA synthesis and inhibits tumor cell growth. Trifluridine (TFT) is incorporated into DNA by phosphorylation by thymidylate kinase (TK) to TF-TMP; TF-TMP then covalently binds to tyrosine 146 of the active site of thymidylate synthase (TS) inhibiting the enzyme's activity. TS is vital to the synthesis of DNA because it is an enzyme involved in the synthesis of the deoxynucleotide, thymidine triphosphate (dTTP). Inhibition of TS depletes the cell of dTTP and causes accumulation of deoxyuridine monophosphate (dUMP), which increases the likelihood that uracil gets misincorporated into the DNA.
Study NCT05563558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Included in arm/group description
Study NCT05563558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Included in arm/group description
Study NCT05563558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Included in arm/group description
Study NCT05327452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Home-Based Exercise
Description: Online supervised aerobic and resistance exercise
Study NCT05327452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unsupervised Home-Based Exercise
Description: Unsupervised aerobic and resistance exercise (UNSUP)
Study NCT05327452 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Stretching Program
Study NCT04578665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Interaction Conditions
Description: The participants will be single-blinded and complete a tracking task as either: solo task, collaboration task (both participants work on a common task synchronously to achieve a goal; this is a summative effort to achieve the goal), competition task (each participant has to achieve a goal at the expense of his or her partner, therefore maximizing effort or error of the partner in reaching the goal), or cooperation task (an asymmetric partnership with an active partner and a passive partner working towards a goal).
Study NCT04578665 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Haptic Impedance Level
Description: The subjects will complete their task at 3 impedance levels: high (a virtual stiffness 160-200 N/m and damping 0\~10 Nm/s; this will be a stiff connection in which the subjects feel like they are connected via rigid links and each subject will perceive the other partner's movement directly), medium (a virtual stiffness 100-140 N/m and damping 0\~10 Nm/s; this will be a spring like-connection in which the subjects feel like they are connected with a spring and each subject will perceive the other partner with a force that is proportional to the trajectory difference of the two participants), and soft (a virtual stiffness 40-80 N/m and damping 0\~10 Nm/s; this will be a spring like connection in which the subjects feel like they are connected with a loose spring and each subject will perceive the other partner with a force that is proportional to the trajectory difference of the two subjects, however, this force will be smaller than that of the medium impedance).
Study NCT04578665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skill Level of Partner
Description: There will be two skill levels: novice (a participant who has no prior experience with the trajectory tracking experiment; in testing with the clinical populations, the investigators will assign this condition to the clinical participant) and expert (a participant who is experienced with the trajectory tracking experiment and who can achieve a tracking error \[difference of the desired trajectory and actual trajectory\] below a certain threshold; in testing with the clinical population, the investigators will assign this condition to the therapist). Participants will start experimentation paired as novice-novice, and at the end of the session may be invited to continue additional sessions to be paired as the expert in a novice-expert dyad.
Study NCT04578665 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot Controller Showcase
Description: The subjects will complete 10 training sessions per assistive robot for the researchers to observe motor learning and functional outcomes.
Study NCT05430906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104 - Chemotherapy
Description: AK104 10mg/kg then \[paclitaxel (135-175 mg/m²) or docetaxel (75 mg/m²)\] and \[carboplatin (AUC5 or 6) or cisplatin (75mg/m²)\] of each 21-day cycle
Study NCT06130995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix and Enzalutamide
Description: Dose level of Relugolix and Enzalutamide Safety Lead-in Cohort, 3-12 patient. Relugolix;120 mg, oral, once daily, with a loading dose of 360 mg on day 1, Enzalutamide; 120-160 mg, oral, once daily.~Dose Expansion Cohort, up to 34 patients. Relugolix;120 mg, oral, once daily, with a loading dose of 360 mg on day 1, Enzalutamide; To be determined by safety lead-in cohort.~One cycle = 3 months The dose limiting toxicity (DLT) period is the first 28 days~Neoadjuvant ADT: 6 months; Relugolix: 120 mg orally, daily (with a 360 mg loading dose on day 1, Enzalutamide: 160 mg (or 120 mg) orally, daily~Concurrent ADT during Radiation Therapy; Relugolix: 120 mg orally, daily (with a 360 mg loading dose on day 1, Enzalutamide: 160 mg (or 120 mg) orally, daily~Maintenance ADT: Additional 18 months; Relugolix: 120 mg orally, daily (with a 360 mg loading dose on day 1, Enzalutamide: 160 mg (or 120 mg) orally, daily
Study NCT05111717 — intervention group
Intervention type: DRUG
Intervention: Desflurane
Description: Peripheral venous blood samplesof patients will collected at two time points as follows: before the premedication and the induction of anesthesia (T₁): 120 minutes after the beginning of anesthesia (T₂). Anesthesia maintenance will be provided with 40% O₂ and minimum alveolar concentration (MAC) in 60% air with 6% desflurane. DNA will be obtained from blood samples with the help of DNA isolation kit, and global DNA methylation analysis will performed by ELISA method.
Study NCT05087589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Tofacitinib 5mg was taken orally twice a day for 6 months
Study NCT05081388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN14256
Description: Sub-cutaneous (SC) single dose
Study NCT05081388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imdevimab
Description: SC single dose
Study NCT05081388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: casirivimab + imdevimab
Description: SC single dose
Study NCT05081388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SC single dose
Study NCT03946423 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric Surgery with Sleeve Gastrectomy
Description: Standard of care bariatric surgery with sleeve gastrectomy
Study NCT03946423 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Intervention
Description: All participants receive lifestyle intervention. The lifestyle intervention program is modeled closely after that used in the Diabetes Primary Prevention Trial and the LookAHEAD diabetes treatment studies. Intervention includes counseling sessions weekly for the first six months, twice a month during months 7-9, and monthly during months 10-12, and energy intake and exercise goal monitoring and guidance.
Study NCT03946423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: All participants receive lifestyle intervention. The lifestyle intervention program is modeled closely after that used in the Diabetes Primary Prevention Trial and the LookAHEAD diabetes treatment studies. Intervention includes counseling sessions weekly for the first six months, twice a month during months 7-9, and monthly during months 10-12, and energy intake and exercise goal monitoring and guidance.
Study NCT04541121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3D printed model
Description: Mother is given 3D printed model of fetus' face
Study NCT04541121 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mother is given a picture of 3D ultrasound of fetus
Study NCT06342232 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback mindfulness
Description: The participants used a portable EEG headband to complete 10 minutes of neurofeedback mindfulness practice for 8 weeks. While being seated comfortably, they could modify their brains rates based on the audio neurofeedback they received.
Study NCT06342232 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Simple attention controlled task
Description: The controlled group of this project also received an intervention which included an audiobook. While wearing the headband, the controlled participants muted their neurofeedback sounds and only focused on an audiobook while remaining relaxed. A summary of their brain states was given to them when completing their practice every day.
Study NCT05067855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercise program group
Description: Pilates exercise program group will do a warm-up for 10 minutes and then perform five exercises includes standing footwork, hundreds with knee straight, articulating bridge, rolling like a ball, plank for 25 minutes. For first three weeks, each player will do 8 repetitions × 3 sets of exercises and for next three weeks, each player will do 15 repetitions × 3 sets of exercises. There will be cool-down for 10 minutes after exercises. Total program will be of 45 minutes.
Study NCT06247150 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Additional blood sample
Description: The procedure will consist of an additional blood sample for 3 ETDA tubes collection (NGS analysis) and citrate tube collection (NETose analysis)
Study NCT06247150 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: cGVHD target tissue biopsy
Description: For chronic GVH patients only, cGVHD target tissue biopsy
Study NCT05524753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AquOTic
Description: group-based aquatic occupational therapy sessions with 1:1 support
Study NCT05089214 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra oral cameras
Description: Diagnostic comparison of two intra oral cameras
Study NCT04824001 — intervention group
Intervention type: OTHER
Intervention: exercise stress echocardiography
Description: Stress echocardiography test. The standardized exercise test was conducted by 50-W semi-recumbent cycling for 3 min. Stress echocardiograph images were acquired at the third minute of cycling to ensure that subjects had reached a steady-state HR.
Study NCT05916222 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dynamic Temporal and Tactile Cueing (DTTC)
Description: DTTC is a motor-based intervention where the client watches, listens to and imitates the clinician (Strand, 2020). Treatment follows a temporal hierarchy where children receive multisensory cueing to establish accurate movements. First, the child imitates the clinician's production. If inaccurate, the child simultaneously produces the target with the clinician while cueing is provided. Upon achieving accuracy within simultaneous productions, the target is practiced within direct imitation while the clinician adds/fades cues based on the child's productions. When the child accurately produces the target in direct imitation, the target is practiced with varied prosody. Next, the target is practiced within delayed imitation where a child produces a word following a 2-3 second delay after the clinician's production. Upon accurately producing the target at all levels, the word is practiced within spontaneous productions.
Study NCT05916222 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Temporal and Tactile Cueing (DTTC)
Description: DTTC is a motor-based intervention where the client watches, listens to and imitates the clinician (Strand, 2020). Treatment follows a temporal hierarchy where children receive multisensory cueing to establish accurate movements. First, the child imitates the clinician's production. If inaccurate, the child simultaneously produces the target with the clinician while cueing is provided. Upon achieving accuracy within simultaneous productions, the target is practiced within direct imitation while the clinician adds/fades cues based on the child's productions. When the child accurately produces the target in direct imitation, the target is practiced with varied prosody. Next, the target is practiced within delayed imitation where a child produces a word following a 2-3 second delay after the clinician's production. Upon accurately producing the target at all levels, the word is practiced within spontaneous productions.
Study NCT06414863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPE
Description: Invisalign palatal expander system:~The Invisalign® Palatal Expander System (AlignTechnology, inc.) is 3D-printed orthodontic device for maxillary expansion.
Study NCT06414863 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HE
Description: Hyrax expander:~The Hyrax-type maxillary expander will include a midline self-locking screw. The expansion screw is connected to the conventional molar bands or printed clasps, which are cemented on the maxillary first molars (or on the maxillary primary second molars), via 0.9 mm stainless-steel wire. The framework is soldered to the bands and extends on the palatal side to the primary canines or canines. The expander will be fabricated by a qualified laboratory technician
Study NCT04189016 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inhalation from a salt particle inhaler with or without content
Description: Inhalation from inhaler with (active) or without (placebo) content
Study NCT04189016 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Inhalation from a salt particle inhaler with or without content
Description: Inhalation from inhaler with (active) or without (placebo) content
Study NCT05363228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy by Dance and Movement
Description: Therapy by dance and movement is based on the principals of movement-analysis by Rudolf Laban and Irmgard Bartenieff. Participants will attend sessions twice a week (90 minutes each) for the duration of three months.
Study NCT05363228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: Tai Chi is based on somatic approach. Participants will attend sessions twice a week (90 minutes each) for the duration of three months.
Study NCT05966298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stabilization training
Description: First, while focusing on the activation methods of deep cervical flexor, transversus abdominus and multifidus muscles in individuals; In the next stages, exercises will be performed that will preserve the contraction of the deep cervical flexor, transversus abdominus and multifidus muscles and activate the other muscles of the body.